Marina Inks $1M Licensing Deal with Novartis for Oligo Technology | GenomeWeb

Marina Biotech announced last week that it has non-exclusively licensed its conformationally restricted nucleotide technology to Novartis for $1 million in upfront fees.

CRNs are essentially nucleotide analogs to which the C2' and C4' carbon bonds of the ribose ring are linked, which promotes increased hybridization affinity, according to Marina.

Additional terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.